Trials / Completed
CompletedNCT02178722
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 444 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
- Endometrial Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Gastric Cancer
- Lung Cancer
- Lymphoma
- Renal Cell Carcinoma (RCC)
- Ovarian Cancer
- Solid Tumors
- UC (Urothelial Cancer)
- Melanoma
- Bladder Cancer
- Triple Negative Breast Cancer (TNBC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-3475 | IV infusion |
| DRUG | INCB024360 | Oral daily dosing |
Timeline
- Start date
- 2014-07-17
- Primary completion
- 2018-11-26
- Completion
- 2020-11-06
- First posted
- 2014-07-01
- Last updated
- 2022-02-14
- Results posted
- 2019-12-19
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02178722. Inclusion in this directory is not an endorsement.